Duan Rui-Dong, Hindorf Ulf, Cheng Yajun, Bergenzaun Per, Hall Mats, Hertervig Erik, Nilsson Åke
Gastroenterology & Nutrition Laboratory, BMC, B11, Department of Clinical Sciences in Lund, University of Lund, S-22184 Lund, Sweden.
BMC Gastroenterol. 2014 Aug 7;14:138. doi: 10.1186/1471-230X-14-138.
Alkaline sphingomyelinase (NPP7) is an ecto-enzyme expressed in intestinal mucosa, which hydrolyses sphingomyelin (SM) to ceramide and inactivates platelet activating factor. It is also expressed in human liver and released in the bile. The enzyme may have anti-tumour and anti-inflammatory effects in colon and its levels are decreased in patients with colon cancer and ulcerative colitis. Active NPP7 is translated from a transcript of 1.4 kb, whereas an inactive form from a 1.2 kb mRNA was found in colon and liver cancer cell lines. While the roles of NPP7 in colon cancer have been intensively studied, less is known about the function and implications of NPP7 in the bile. The present study examines the changes of NPP7 in bile of patients with various hepatobiliary diseases.
Bile samples were obtained at endoscopic retrograde cholangiopancreatography (ERCP) in 59 patients with gallstone, other benign disease, tumour, and primary sclerosing cholangitis (PSC). The NPP7 activity was determined. The appearance of the 1.4 and 1.2 kb products in the bile was examined by Western blot. The results were correlated to the diseases and also plasma bilirubin and alkaline phosphatase.
NPP7 activity in the tumour group was significantly lower than in the gallstone group (p < 0.05). The activity in the tumour plus PSC group was also lower than in gallstone plus other benign disease group (p < 0.05). Within the tumour group NPP7 activity was lowest in cholangiocarcinoma patients, being only 19% of that in gallstone patients. Bilirubin correlated inversely to NPP7 and was higher in the tumour than in the gallstone group. Western blot identified both the 1.4 kb and the 1.2 kb products in most bile samples. The density ratio for the 1.4/1.2 kb products correlated to NPP7 activity significantly. Two patients (one PSC and one cholangiocarcinoma) lacking NPP7 activity had only the 1.2 kb form in bile.
NPP7 activity and the ratio of 1.4/1.2 kb products in bile are significantly decreased in malignancy, particularly in cholangiocarcinoma. The implications of the finding in diagnosis of cholangiocarcinoma and 1.2 kb product in hepatobiliary diseases require further investigation.
碱性鞘磷脂酶(NPP7)是一种在肠黏膜中表达的胞外酶,它将鞘磷脂(SM)水解为神经酰胺并使血小板活化因子失活。它也在人肝脏中表达并释放到胆汁中。该酶在结肠中可能具有抗肿瘤和抗炎作用,在结肠癌和溃疡性结肠炎患者中其水平降低。活性NPP7由1.4 kb的转录本翻译而来,而在结肠癌和肝癌细胞系中发现了由1.2 kb mRNA产生的无活性形式。虽然NPP7在结肠癌中的作用已得到深入研究,但关于NPP7在胆汁中的功能和影响知之甚少。本研究检测了各种肝胆疾病患者胆汁中NPP7的变化。
对59例患有胆结石、其他良性疾病、肿瘤和原发性硬化性胆管炎(PSC)的患者,在内镜逆行胰胆管造影(ERCP)时获取胆汁样本。测定NPP7活性。通过蛋白质免疫印迹法检测胆汁中1.4 kb和1.2 kb产物的出现情况。将结果与疾病以及血浆胆红素和碱性磷酸酶进行关联分析。
肿瘤组的NPP7活性显著低于胆结石组(p < 0.05)。肿瘤加PSC组的活性也低于胆结石加其他良性疾病组(p < 0.05)。在肿瘤组中,胆管癌患者的NPP7活性最低,仅为胆结石患者的19%。胆红素与NPP7呈负相关,且在肿瘤组中高于胆结石组。蛋白质免疫印迹法在大多数胆汁样本中鉴定出了1.4 kb和1.2 kb的产物。1.4/1.2 kb产物的密度比与NPP7活性显著相关。两名缺乏NPP7活性的患者(一名PSC患者和一名胆管癌患者)胆汁中仅存在1.2 kb形式的产物。
恶性肿瘤,尤其是胆管癌患者胆汁中的NPP7活性以及1.4/1.2 kb产物的比例显著降低。这一发现对胆管癌诊断的意义以及肝胆疾病中1.2 kb产物的意义需要进一步研究。